TNXP
Tonix Pharmaceuticals Holding Corp.
NASDAQ · Healthcare · Biotechnology · US
$5.73
−5.13%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$6.15
From 52W high−71.84%
Volume1.30M
Market cap$98.28M
P/E (TTM)—
P/S (TTM)3.4x
Div yield—
Key dataOct 19, 2026
Open
$6.15
From 52W high
−71.84%
Volume
1.30M
Market cap
$98.28M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
0.5x
P/E (TTM)
—
RSI (14)
14.7
MomentumView details →
1D Return
−5.13%
YTD Return
−62.93%
SummaryUpdated Jun 1, 2026
Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) is a clinical-stage biopharmaceutical company founded in 2007 and headquartered in Chatham, New Jersey. The company went public in May 2012 and focuses on discovering, acquiring, developing, and licensing therapeutics and diagnostics across multiple therapeutic areas. Tonix operates as a development-stage company with a diverse pipeline of drug candidates targeting immunology, rare diseases, infectious diseases, and central nervous system conditions, though it has yet to bring any products to market and remains in the clinical development phase.
Similar companies
Latest newsMore news →
Tonix Pharmaceuticals announced that a poster analyzing Phase 3 data on TONMYA will be presented at the IASP 2026 World Congress on Pain in Bangkok from October 26 to 30, 2026.13h agoTonix Pharmaceuticals announced an oral presentation on its investigational TNX-801 vaccine platform and a working group session it will lead at the World Vaccine Congress Europe in Amsterdam on October 19–21, 2026.5d agoTonix Pharmaceuticals announced a second major managed Medicare payer agreement for its fibromyalgia treatment TONMYA, effective immediately, adding approximately 21 million Medicare lives.28d ago